DE Furst, FC Breedveld, JR Kalden, JS … - British Medical Journal, 2007 - ard.bmj.com As in previous years, the consensus group to consider the use of biological
agents was constituted by rheumatologists from the universities of Erlangen,
Leiden and Vienna in Europe in cooperation with other universities in the ... Cited by 78 - Related articles - BL Direct - All 5 versions
LL Lim, FW Fraunfelder, JT Rosenbaum - Arthritis Care & Research - interscience.wiley.com Dr. Fraunfelder has received consulting fees (less than $10,000 each) from
Novartis and Eli Lilly. Dr. Rosenbaum has received consulting fees (less than
$10,000) from Abbott Laboratories. Oregon Health and Science University ... Cited by 30 - Related articles - BL Direct - All 2 versions
DE Furst, EC Keystone, B Kirkham, R … - British Medical Journal, 2008 - ard.bmj.com As in previous years, the consensus group to consider the use of biological
agents in the treatment of rheumatic diseases met during the 10th Annual
Workshop on Advances in Targeted Therapies. The group consisted of ... Cited by 29 - Related articles - All 6 versions
A Barrie, M Regueiro - Inflammatory Bowel Diseases, 2007 - ccmjournal.org From the Weil Institute of Critical Care Medicine, Rancho Mirage, CA (TW, WT,
SS, GR, MHW); Department of Emergency Medicine, The Second Affiliated Hospital
of Sun Yat-sen University, Guangzhou, China (TW, WT, ZH); and Keck School ... Cited by 22 - Related articles - BL Direct - All 3 versions
SP Ardoin, D Kredich, E Rabinovich, LE … - American Journal of Ophthalmology, 2007 - Elsevier Of sixteen children (29 affected eyes) with median age 11 years, six had
associated extraocular inflammatory conditions. Fifteen of 16 were treated with
concomitant methotrexate. Median follow-up was 26 months and median ... Cited by 19 - Related articles - All 25 versions
- ►duanessolution.com FR Imrie, AD Dick - Current Opinion in Ophthalmology, 2007 - journals.lww.com Recent findings: The anti-tumour necrosis factor-α infliximab and adalimumab
have demonstrated significant efficacy in controlling uveitis associated with
seronegative spondyloarthropathies and juvenile idiopathic arthritis; ... Cited by 18 - Related articles - BL Direct - All 4 versions
M Gallagher, K Quinones, RA Cervantes- … - British Journal of Ophthalmology, 2007 - bjo.bmj.com Methods: All children (18 years or younger) who received a BRM were assessed for
visual changes, time to control inflammation, and any associated adverse side
effects. Thirteen patients were treated with infliximab, five with ... Cited by 16 - Related articles - BL Direct - All 4 versions
- ►oxfordjournals.org P Tynjala, K Kotaniemi, P Lindahl, K Latva, … - Rheumatology, 2008 - Br Soc Rheumatology 1 Department of Pediatric Rheumatology, Hospital for Children and Adolescents,
Helsinki University Central Hospital, 2 Department of Pediatrics, Lohja
Hospital, Lohja, 3 Department of Ophthalmology, Rheumatism Foundation ... Cited by 12 - Related articles - BL Direct - All 4 versions
NT Ilowite - Current Opinion in Rheumatology, 2008 - journals.lww.com Recent findings: The results of a pivotal trial of infliximab in polyarticular
juvenile idiopathic arthritis suggested efficacy, but the primary outcome was
not significantly different from placebo. Important information regarding ... Cited by 10 - Related articles - All 3 versions
FR Imrie, AD Dick - Current Opinion in Ophthalmology, 2007 - journals.lww.com Purpose of review This review summarizes current nonsteroidal drug therapies for
noninfectious posterior and intermediate uveitis. Recent findings Continuing
evidence shows that second-line agents including antimetabolites, T-cell ... Cited by 9 - Related articles - BL Direct - All 2 versions
